Dementia With Lewy Bodies Clinical Trial
Official title:
An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies
Verified date | June 2013 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This research study is to examine the effects of the study medication Armodafinil in
patients with dementia with Lewy bodies (DLB).
DLB is associated with memory and other thinking problems, excessive daytime sleepiness,
hallucinations, delusions, apathy, and reduced quality of life.
One type of medication that could potentially improve daytime sleepiness, memory and
thinking skills, hallucinations, delusions, apathy, and quality of life is known as a
wake-promoting medication. Armodafinil is a wake-promoting medication that has been
developed for treatment of patients with narcolepsy, sleep apnea, and other disorders which
cause excessive daytime sleepiness.
The drug used in this study is considered investigational, which means it has either not
been approved by the Food and Drug Administration (FDA) for routine clinical use or for the
use described in this study. However the FDA has allowed the use of this drug/device in this
research study.
In this study, patients with DLB will receive daily oral Armodafinil tablets, and their
response to treatment will be assessed over 12 weeks. This study does not involve any
placebo medication, so all patients will receive Armodafinil treatment.
Status | Completed |
Enrollment | 20 |
Est. completion date | March 2012 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of clinically possible or probable DLB using established criteria - Age 50-90 inclusive - Epworth Sleepiness Scale score of 8 or greater - MMSE score between 10 and 26 inclusive - No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol - Stable medication regimen over previous four weeks - Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness - Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) [ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) <15] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA - Caregiver that is with the patient at least 4 hours/day for at least 5 days per week - Patient and caregiver willing and able to participate in all study-related procedures - Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf. Exclusion Criteria: - Does not fulfill criteria for clinically possible or probable DLB - Age <50 or >90 - Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative - Epworth Sleepiness Scale score less than 8 - MMSE score <10 or >26 - Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as: - Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic - Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants - Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease - History of left ventricular hypertrophy or mitral valve prolapse - History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia - History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin) - History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) - Pulmonary disease requiring oral or inhalatory medications - Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication - Medication regimen has not been stable over preceding four weeks - Concurrent use of lamotrigine or oxcarbazepine - Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as: - Clonazepam > 1 mg/night - Seroquel > 100 mg/night - Zyprexa > 10 mg/night - Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated - Clinically significant abnormalities on screening ECG or laboratory tests - Patient or caregiver unwilling or unable to participate in all study-related procedures - Caregiver is not with patient at least 4 hours/day for at least 5 days/week - Patient or caregiver unwilling or unable to provide informed consent - CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | Cephalon, National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) | The MWT measures the subject's ability to stay awake while sitting quietly in a chair. The test has 4 parts, each lasting 40 minutes if the subject is able to remain awake that long each time, and the parts are spaced apart in 2 hour intervals through the day. The subject is placed in a dim room, with the only source of light slightly behind the subject's head and out of his/her field of vision, and back and neck supported. During this time the subject is monitored with the same measures that are used in a standard overnight sleep study called a polysomnogram. The sleep latency, or time it takes the subject to fall asleep, will be recorded. In healthy people, the time it takes to fall asleep may be approximately 30 minutes on the test. More than 97% of people will take eight minutes or longer to fall asleep. Therefore, sleep latency that is less than eight minutes is considered to be abnormal. |
baseline, 12 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03996460 -
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT03672448 -
The China Longitudinal Aging Study of Cognitive Impairment
|
||
Completed |
NCT01340001 -
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
|
N/A | |
Not yet recruiting |
NCT04760860 -
Terazosin for Dementia With Lewy Bodies
|
Phase 1/Phase 2 | |
Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
Terminated |
NCT02928445 -
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
|
Phase 2/Phase 3 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Completed |
NCT05188105 -
Alpha tACS in Dementia With Lewy Bodies
|
N/A | |
Active, not recruiting |
NCT04167813 -
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
|
Phase 2 | |
Enrolling by invitation |
NCT04954183 -
Development of an EEG Diagnostic for Alzheimer's Disease
|
||
Recruiting |
NCT05326750 -
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
|
N/A | |
Completed |
NCT03907748 -
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
|
N/A | |
Completed |
NCT04649164 -
Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
|
N/A | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Completed |
NCT05885620 -
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
|
N/A | |
Not yet recruiting |
NCT04555629 -
Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK)
|
N/A |